152 related articles for article (PubMed ID: 37290395)
21. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
22. Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
Tsai HL; Chen YT; Yeh YS; Huang CW; Ma CJ; Wang JY
Pathol Oncol Res; 2019 Jul; 25(3):905-913. PubMed ID: 29299827
[TBL] [Abstract][Full Text] [Related]
23. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Moreau LC; Rajan R; Thirlwell MP; Alcindor T
Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
[TBL] [Abstract][Full Text] [Related]
24. The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Ogata Y; Matono K; Mizobe T; Ishibashi N; Mori S; Akagi Y; Ikeda S; Ozasa H; Murakami H; Shirouzu K
Oncol Rep; 2006 May; 15(5):1111-6. PubMed ID: 16596171
[TBL] [Abstract][Full Text] [Related]
25. Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX.
Yoshida Y; Hasegawa J; Nezu R; Kim YK; Hirota M; Kawano K; Izumi H; Kohno K
Cancer Sci; 2011 Mar; 102(3):578-82. PubMed ID: 21205083
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of combining E-cadherin, p53, Bcl-2 and Bcl-xL expression and survival in Tunisian colorectal adenocarcinoma patients.
Jamai D; Kallel I; Mekrezi S; Walha M; Gharsallah M; Khabir A; Selmi B
Cell Mol Biol (Noisy-le-grand); 2022 Apr; 68(4):93-107. PubMed ID: 35988276
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M
Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489
[TBL] [Abstract][Full Text] [Related]
29. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
30. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.
Bates DO; Catalano PJ; Symonds KE; Varey AH; Ramani P; O'Dwyer PJ; Giantonio BJ; Meropol NJ; Benson AB; Harper SJ
Clin Cancer Res; 2012 Nov; 18(22):6384-91. PubMed ID: 23104894
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
[TBL] [Abstract][Full Text] [Related]
32. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
33. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
Oncology; 2011; 80(1-2):84-91. PubMed ID: 21677451
[TBL] [Abstract][Full Text] [Related]
34. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
36. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.
Hansen TF; Christensen Rd; Andersen RF; Garm Spindler KL; Johnsson A; Jakobsen A
Int J Colorectal Dis; 2012 Jun; 27(6):715-20. PubMed ID: 22139032
[TBL] [Abstract][Full Text] [Related]
37. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen.
Kim JW; Im SA; Kim M; Cha Y; Lee KH; Keam B; Kim MA; Han SW; Oh DY; Kim TY; Kim WH; Bang YJ
Anticancer Res; 2012 Apr; 32(4):1547-53. PubMed ID: 22493400
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Akbulut H; Altuntas F; Akbulut KG; Ozturk G; Cindoruk M; Unal E; Icli F
Cytokine; 2002 Nov; 20(4):184-90. PubMed ID: 12543084
[TBL] [Abstract][Full Text] [Related]
40. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
Azzariti A; Porcelli L; Brunetti O; Del Re M; Longo V; Nardulli P; Signorile M; Xu JM; Calabrese A; Quatrale AE; Maiello E; Lorusso V; Silvestris N
World J Gastroenterol; 2016 Jul; 22(27):6287-95. PubMed ID: 27468218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
